On August 10th, 2012 the FDA approved Lucentis 0.3 mg for use in Diabetic Macular Edema.
What does this mean for you? According to the Centers for Disease Control and Prevention, diabetes (type 1 and type 2) affects about 26 million people in the United States and is the leading cause of new blindness among people ages 20 to 74 years. In 2010, 3.9 million adults diagnosed with diabetes reported trouble with their vision.
In the RIDE and RISE trials, phase 3 treatment trials sponsored by Genentech, patients receiving intravitreal Lucentis for diabetic macular edema experienced a statistically significant increase in visual acuity than patients received focal laser alone.
Prior to the era of intravitreal anti-VEGF, focal laser and intravitreal steroids were the only option for trealtment of diabetic macular edema. While these treatments were effective, recent trials have shown that anti-VEGF injections can be more effective for some patients.
We are now offering this new dose at all 5 of our NC Retina Associates locations.
Not all patients are candidates for anti-VEGF therapy for diabetic macular edema. Please consult with your eye care physician.
Please visit us at www.ncretina.com
No comments:
Post a Comment